# Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

> **NCT02536742** · PHASE2 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 124 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02536742
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-30
- **Primary completion:** 2020-08-28
- **Final completion:** 2022-12-22
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536742, "Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02536742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*